In the Lancet Diabetes & Endocrinology, Hertzel Gerstein and colleagues report stroke outcomes from the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial, a cardiovascular outcomes study that investigated the effect of the glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide (1·5 mg subcutaneous weekly) compared with placebo in 9901 participants with type 2 diabetes and increased cardiovascular risk. During a median follow-up of 5·4 years, the primary outcome, a composite of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes, was reduced with dulaglutide compared with placebo (hazard ratio [HR] 0·88, 95% CI 0·79–0·99; p=0·026).

中文翻译：

---

快退一步：是时候重新讨论2型糖尿病的中风预防了吗？

在《柳叶刀糖尿病与内分泌学》中，Hertzel Gerstein及其同事报告了每周一次的糖尿病降血糖素（REWIND）试验研究心血管事件的卒中结局，这项心血管结局研究调查了胰高血糖素样肽1（GLP-1）的作用。在9901名2型糖尿病和心血管风险增加的受试者中，受体激动剂dulaglutide（每周皮下注射1·5 mg）与安慰剂相比。在中位随访5·4年中，与安慰剂相比，度拉鲁肽降低了主要结局，包括非致命性心肌梗死，非致命性中风或心血管原因死亡的复合结果（危险比[HR] 0 ·88，95％CI 0·79-0·99; p = 0·026）。